• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer.
【24h】

Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer.

机译：Galectin-1作为自身免疫性疾病和癌症的潜在治疗靶标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Galectin-1, a member of a family of highly conserved glycan-binding proteins, has emerged as a regulator of immune cell tolerance and homeostasis. This endogenous lectin widely expressed at sites of inflammation and tumour growth, has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin-1 contributes to different steps of tumour progression including cell adhesion, migration and tumour-immune escape, suggesting that blockade of galectin-1 might result in therapeutic benefits in cancer. Recent findings implicating galectin-glycoprotein lattices as selective regulators of inflammatory responses have provided new insights into the understanding of the molecular bases of galectin-1-induced immunoregulation. Here the authors review the dual role of galectin-1 as a selective immunosuppressive agent in T helper (T(H))1 and T(H)17-mediated inflammatory/autoimmune disorders and a potential therapeutic target in cancer and metastasis.
机译：Galectin-1是高度保守的聚糖结合蛋白家族的成员，已成为免疫细胞耐受性和体内平衡的调节剂。这种内源性凝集素在炎症和肿瘤生长部位广泛表达，被认为是一种有吸引力的免疫抑制剂，可在自身免疫和炎症环境中恢复免疫细胞的耐受性和体内稳态。另一方面，galectin-1促成肿瘤进展的不同步骤，包括细胞粘附，迁移和肿瘤免疫逃逸，这表明galectin-1的阻断可能导致癌症的治疗获益。涉及半乳凝素-糖蛋白晶格作为炎症反应的选择性调节剂的最新发现为了解半乳凝素-1诱导的免疫调节的分子基础提供了新的见解。在这里，作者综述了半乳糖凝集素-1（Galectin-1）在T辅助（T（H））1和T（H）17介导的炎性/自身免疫性疾病中的选择性免疫抑制剂的双重作用，以及在癌症和转移中的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号